Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Ilaris Adds Three Rare Disease Claims; Sirukumab Submitted; Exondys 51's Surprising Approval

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Duchenne Development: Six-Minute Walk Losing Favor?
Eteplirsen Review Timeline: CDER Director Was Involved Early And Often
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
Too Little, Too Late For GSK/Janssen's Sirukumab in RA?
Keeping Track: Approvals For Nuplazid, Cabometyx, Bevespi And More; Digital Aripiprazole Tablet Needs More Study
Keeping Track: Mycapssa Stumbles; Carnexiv Returns; Keytruda Follows Opdivo In Hodgkin Lymphoma


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts